Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

56.34 -0.06 (-0.12%)
Streaming Delayed Price Updated: 2:13 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Pharmaceuticals ETF

< Previous 1 2 Next >
News headline image
Pharma ETFs in Focus Post Q2 Earnings ↗
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
News headline image
Pharma ETFs Gain Post Q1 Earnings ↗
Pharma ETFs have been in the green over the past month. 
Via Talk Markets
News headline image
A Look At Pharma ETFs Post Q4 Earnings ↗
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
News headline image
Pharma ETFs In Focus Post Q3 Earnings ↗
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
News headline image
Large Cap Biopharma- Well Positioned For Choppy Markets ↗
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
3 Pharmaceutical ETFs That Could Be Due For A Rebound ↗
These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of bu... 
Via Benzinga
News headline image
3 Pharma Stocks Yielding Over 3% ↗
The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries. 
Via Talk Markets
News headline image
7 Pharmaceutical Stocks That Could Make You Rich ↗
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
News headline image
The Bear Market Is Already Here – But Not For Dividend Investors ↗
While the broad stock market indices remain at near-record levels, there are sectors of the market that have dropped into correction or even bear market territory over recent months. 
Via Talk Markets
News headline image
Wave of Solid Q3 Earnings Push Pharma ETFs Higher ↗
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
Via Talk Markets
News headline image
The Cost Of Saving The Economy: $1.7 Billion Per Hour Every Hour ↗
the Fed has bought $4 trillion bonds in the past 18 months, twice the amount the US spent on War in Afghanistan past 20 years as it, and other global central banks, have spent $834 million every hour... 
Via Talk Markets
Topics Bonds Economy
News headline image
The 2 Best Pharma Stocks to Buy on Dips ↗
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Via Talk Markets
News headline image
3 Top Pharma Stocks to Buy This Month ↗
In 2020, pharmaceutical stocks came to the forefront as healthcare companies were searching for treatments for COVID-19. 
Via Talk Markets
News headline image
Pharma ETFs in Focus Post Q1 Earnings ↗
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
Via Talk Markets
News headline image
3 Pharmaceutical ETFs That Could Be Due For A Rebound ↗
Here are three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.